Ipilimumab belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Ipilimumab targets the immune checkpoint molecule CTLA-4 and allows the body to increase the number of immune cells available to attack and destroy cancer cells.
INCB 99280 is an experimental cancer immune checkpoint inhibitor that targets the PD-L1 molecule. This is similar to Health Canada-approved therapies used in other cancers, such as Avelumab (Bavencia®).
Since this drug is still in the clinical trial phase, it has the placeholder name INCB 99280 rather than a commercial trade name.
This is a phase 1 study that will investigate the safety and effectiveness of INCB 99280 in combination with Ipilimumab among patients with several different cancer types, including kidney cancer.
In order to maximize effectiveness and minimize side effects, different doses of each drug will be used to determine the optimal dosage of these medications.
This is a single-group study, so there is no randomization, no placebo, and all eligible patients will receive treatment.
- IMDC intermediate or poor risk
- Clear cell kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- No prior receipt of immunotherapy
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Center||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusNot yet recruiting|